Advertisement

European Journal of Pediatrics

, Volume 169, Issue 10, pp 1293–1297 | Cite as

Hospitalization of newborns and young infants for chickenpox in France

  • Aurélie LécuyerEmail author
  • Corinne Levy
  • Joel Gaudelus
  • Daniel Floret
  • Benoit Soubeyrand
  • Evelyne Caulin
  • Robert Cohen
  • Emmanuel Grimprel
  • Pediatricians Working Group
Short Report

Abstract

Chickenpox is often considered more severe during the first year of life, but its course is usually mild during the first 3 months of life, presumably owing to the persistence of maternal antibodies. Hospitalization and intravenous acyclovir therapy are generally restricted to severe cases but also systematically recommended in newborns in France, irrespective of the clinical severity of the infection. This recommendation was launched in 1998 when Varicella zoster virus (VZV)-specific immunoglobulins were not available in the country and has remained unchanged since. The aim of this prospective observational study was to describe complications of varicella infection in a population of 745 children hospitalized for varicella before 1 year of age, with a specific focus on newborns. Complications occurred in 65% of cases. They were very rare before the age of 1 month (10%) but their incidence then increased progressively with age and probably the disappearance of maternal antibodies: 42% (1–2 months), 66% (3–5 months), 70% (6–8 months), and 79% (9–12 months). Conclusion Chickenpox is usually mild in newborns because most of them are protected by VZV maternal antibodies. Unless the absence of maternal VZV immunity is demonstrated, newborns with mild chickenpox should not require antiviral therapy.

Keywords

Varicella Epidemiology Infectious diseases Pediatric practice Virology Infants 

Notes

Acknowledgments

The authors express their grateful thanks to all the participants in the study.

Financial support was given by Laboratoire Sanofi Pasteur MSD, Groupe de Pathologie Infectieuse Pédiatrique de la Société Française de Pédiatrie (GPIP), and Association Clinique et Thérapeutique Infantile du Val de Marne (ACTIV). M. Boucherat for the design of the data base, M. Pereira and S. Tortorelli for their technical assistance.

Competing interest

No author has commercial or other association that might pose a conflict of interest. Benoit Soubeyrand and Evelyne Caulin are employed by Laboratoire Sanofi Pasteur MSD.

References

  1. 1.
    Aebi C, Fischer K, Gorgievski M et al (2001) Age-specific seroprevalence to varicella-zoster virus: study in Swiss children and analysis of European data. Vaccine 9:3097–3103CrossRefGoogle Scholar
  2. 2.
    Anonymous (1998) French consensus conference of VZV infections. Méd Mal Inf 28:692–712CrossRefGoogle Scholar
  3. 3.
    Boëlle PY, Hanslik T (2002) Varicella in non-immune persons: incidence, hospitalization and mortality rates. Epidemiol Infect 129:599–606CrossRefPubMedGoogle Scholar
  4. 4.
    Dubos F, Grandbastien B, Hue V et al (2008) Epidemiology of hospital admissions for paediatric varicella infections: a one-year prospective survey in the pre-vaccine era. Epidemiol Infect 135(1):131–138CrossRefGoogle Scholar
  5. 5.
    Gershon AA, Raker R, Steinberg S (1976) Antibody to Varicella-Zoster virus in parturient women and their offspring during the first year of life. Pediatrics 58:692–696PubMedGoogle Scholar
  6. 6.
    Grimprel E, Levy C, de La Rocque F et al (2007) Paediatric varicella hospitalisations in France: a nationwide survey. Clin Microbiol Infect 13:546–549CrossRefPubMedGoogle Scholar
  7. 7.
    Heininger U, Desgrandchamps D, Schaad UB (2006) Seroprevalence of Varicella-Zoster virus IgG antibodies in Swiss children during the first 16 months of age. Vaccine 24:3258–3260CrossRefPubMedGoogle Scholar
  8. 8.
    Heuchan AM, Isaacs D, on behalf of the Australasian Subgroup in Paediatric Infectious Diseases of the Australasian Society for Infectious Diseases (2001) The management of varicella-zoster virus exposure and infection in pregnancy and the newborn period. MJA 174:288–292PubMedGoogle Scholar
  9. 9.
    Khoshnood B, Debruyne M, Lancon F et al (2006) Seroprevalence of varicella in the French population. Pediatr Infect Dis J 25:41–44CrossRefPubMedGoogle Scholar
  10. 10.
    Ooi PL, Goh KT, Doraisingham S, Ling AE (1992) Prevalence of varicella-zoster virus infection in Singapore. Southeast Asian J Trop Med Public Health 23:22–25PubMedGoogle Scholar
  11. 11.
    Ozaki T, Nagai H, Kimura T et al (1980) The age distribution of neutralizing antibodies against varicella-zoster virus in healthy individuals. Biken J 23:9–14PubMedGoogle Scholar
  12. 12.
    Peterson CL, Mascola L, Chao SM et al (1996) Children hospitalized for varicella: a prevaccine review. J Pediatr 129:529–536CrossRefPubMedGoogle Scholar
  13. 13.
    Pickering L, Baker C, Mc Millan J, Long S (2006) Varicella-Zoster infections. In: Pickering L, Baker C, Mc Millan J, Long S (eds) Red Book: 2006 Report of the Committee on Infectious Diseases. 27 ed: American Academy of Pediatrics 711–725Google Scholar
  14. 14.
    Pinquier D, Gagneur A, Balu L (2009) Prevalence of anti-Varicella-Zoster virus antibodies in French infants below 15 months of age. Clin Vaccine Immunol 16:484–487CrossRefPubMedGoogle Scholar
  15. 15.
    Preblud SR, Bregman DJ, Vernon LL (1985) Deaths from varicella in infants. Pediatr Infect Dis 4:503–507CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Aurélie Lécuyer
    • 1
    • 2
    Email author
  • Corinne Levy
    • 1
    • 2
  • Joel Gaudelus
    • 2
  • Daniel Floret
    • 2
  • Benoit Soubeyrand
    • 3
  • Evelyne Caulin
    • 3
  • Robert Cohen
    • 2
    • 4
  • Emmanuel Grimprel
    • 2
  • Pediatricians Working Group
    • 2
  1. 1.Association Clinique et Thérapeutique Infantile du Val de Marne (ACTIV)Saint Maur des FossésFrance
  2. 2.Groupe de Pathologie Infectieuse Pédiatrique de la Société Française de Pédiatrie (GPIP)ParisFrance
  3. 3.Laboratoire Sanofi Pasteur MSDLyonFrance
  4. 4.Centre Hospitalier Intercommunal de CréteilCréteilFrance

Personalised recommendations